EVMN Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

20.790

Open

19.890

VWAP

20.00

Vol

527.00K

Mkt Cap

639.00M

Low

18.840

Amount

11.00M

EV/EBITDA(TTM)

Total Shares

32.00M

817.00M

EV/OCF(TTM)

P/S(TTM)

Evommune, Inc. is a clinical-stage biotechnology company developing therapies that target key drivers of chronic inflammatory diseases. Its initial clinical development programs are focusing on chronic spontaneous urticaria (CSU), atopic dermatitis (AD) and ulcerative colitis (UC). Its product candidates include EVO756 and EVO301. The Company's advanced clinical-stage product candidate, EVO756, is a potent and highly selective oral small molecule antagonist of MRGPRX2, a receptor predominantly found on mast cells and peripheral sensory neurons, which is initially being evaluated in Phase II trials for the treatment of CSU and AD. The Company's second clinical-stage product candidate, EVO301, is a long-acting fusion protein consisting of an IL-18 binding protein (BP) and an anti-serum albumin Fab-associated (SAFA) domain, which is being evaluated in Phase II trials for the treatment of AD and UC.

Events Timeline

(ET)

2025-12-11

18:40:00

U.S. Equity Futures Mixed, Tech Stocks Underperform

2025-12-11

16:20:00

Evommune Reports Q3 Revenue of $10M

2025-12-01 (ET)

2025-12-01

10:00:00

Goldman Sachs Upgrades Chime to Buy with $27 Price Target

2025-12-01

07:50:00

Leerink Initiates Coverage of Evommune with Outperform Rating and $42 Price Target

News

8.5

01-09renaissancecapital

Aktis Oncology Launches $200 Million IPO with $100 Million Investment from Eli Lilly

4.0

01-06Benzinga

Analysts Adjust Ratings on Wealthfront and Spire Global with Price Targets

8.5

2025-12-19Newsfilter

Aktis Oncology Files for IPO in the U.S. Targeting $346 Million in Funding

9.5

2025-12-19Benzinga

Carnival Reports Robust Q4 Earnings, Alongside Amicus Therapeutics, Biomarin Pharmaceutical, and Other Major Stocks Rising on Friday

9.5

2025-12-11Newsfilter

Evommune Raises $172.5M in IPO to Advance Key Clinical Trials

9.0

2025-12-01Benzinga

Analyst Predicts $5 Billion Peak Sales for Evommune's Skin Disorder Treatment, Calling It a 'Blockbuster Commercial Opportunity'

7 Analyst Rating

Wall Street analysts forecast EVMN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EVMN is 38.60 USD with a low forecast of 35.00 USD and a high forecast of 42.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

35.00

Averages

38.60

High

42.00

Current: 0.000

Low

35.00

Averages

38.60

High

42.00

Oppenheimer

Outperform

initiated

$42

AI Analysis

2026-01-22

Reason

Oppenheimer

Price Target

$42

AI Analysis

2026-01-22

initiated

Outperform

Reason

Oppenheimer initiated coverage of Evommune with an Outperform rating and $42 price target. The firm sees an attractive setup heading into three Phase 2 readouts this year for EVO756 in chronic spontaneous urticaria, atopic dermatitis, and EVO301 in AD. Oppenheimer thinks positive Phase 2 results in CIndU should translate to CSU given their shared mast-cell-driven pathophysiology and believes oral EVO756 is well-positioned to address high unmet need in CSU/atopic dermatitis. The firm sees an attractive risk/reward ahead of value-driving catalysts, potentially sending shares up 50%-100% for each readout and making Evommune an attractive acquisition target given broad applicability across I&I.

Raymond James

Strong Buy

initiated

$40

2026-01-07

Reason

Raymond James

Price Target

$40

2026-01-07

initiated

Strong Buy

Reason

Raymond James initiated coverage of Evommune with a Strong Buy rating and $40 price target. The firm views 2026 as a "catalyst-rich year" for Evommune. The shares at current levels offer a "compelling" risk/reward portfolio with "multiple ways to win," the analyst tells investors in a research note. Raymond James believes the company's chronic spontaneous urticaria readout in the first half of 2026 will attract the greatest investor attention.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for EVMN

Unlock Now

Valuation Metrics

The current forward P/E ratio for Evommune Inc (EVMN.N) is -5.38, compared to its 5-year average forward P/E of -5.83. For a more detailed relative valuation and DCF analysis to assess Evommune Inc 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.83

Current PE

-5.38

Overvalued PE

-5.34

Undervalued PE

-6.32

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-7.26

Current EV/EBITDA

-7.05

Overvalued EV/EBITDA

-6.89

Undervalued EV/EBITDA

-7.63

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

344.09

Current PS

327.40

Overvalued PS

368.22

Undervalued PS

319.96

Financials

AI Analysis

Annual

Quarterly

Whales Holding EVMN

RA Capital Management, L.P.

Trading Trends

People Also Watch

Frequently Asked Questions

What is Evommune Inc (EVMN) stock price today?

The current price of EVMN is 20.49 USD — it has increased 4.54 % in the last trading day.

What is Evommune Inc (EVMN)'s business?

What is the price predicton of EVMN Stock?

Wall Street analysts forecast EVMN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EVMN is38.60 USD with a low forecast of 35.00 USD and a high forecast of 42.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Evommune Inc (EVMN)'s revenue for the last quarter?

Evommune Inc revenue for the last quarter amounts to 100.00 USD, decreased 0.00 % YoY.

What is Evommune Inc (EVMN)'s earnings per share (EPS) for the last quarter?

Evommune Inc. EPS for the last quarter amounts to USD, decreased % YoY.

How many employees does Evommune Inc (EVMN). have?

Evommune Inc (EVMN) has 0 emplpoyees as of January 29 2026.

What is Evommune Inc (EVMN) market cap?

Today EVMN has the market capitalization of 639.00M USD.

EVMN Overview

EVMN Overview

Events Timeline

News

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Whales Holding EVMN

Trading Trends

People Also Watch

Frequently Asked Questions

What is Evommune Inc (EVMN) stock price today?

What is Evommune Inc (EVMN)'s business?

What is the price predicton of EVMN Stock?

What is Evommune Inc (EVMN)'s revenue for the last quarter?

What is Evommune Inc (EVMN)'s earnings per share (EPS) for the last quarter?

How many employees does Evommune Inc (EVMN). have?

What is Evommune Inc (EVMN) market cap?